Protein stability is the most crucial factor in protein pharmaceutical preparations. Various techniques were applied for producing stable protein formulations such as spray-drying and freeze-drying. However, heating and freezing stresses are disadvantages for proteins using these methods, respectively. Accordingly, excipients have been used to preserve therapeutic effects of proteins during processing and for long period of time. Therefore, influences of Copovidone, Eudragit® RL-PO and Kollicoat® MAE-30 DP (as excipients) on stability and integrity of lysozyme (as a model protein) in spray-dried and freeze-dried forms were investigated. Protein formulations in both dried forms were prepared without and with the addition of mentioned excipients at different concentrations. Protein formulations were characterised for yield determination, morphology using scanning electron microscopic (SEM), thermal analysis by Differential Scanning Calorimetry (DSC), secondary structure stability using Fourier transform infrared (FT-IR) spectroscopy and biological activity. All protein formulations were subjected to a stability study as solid protein formulations for 3 weeks at 24 °C/76% relative humidity and aqueous protein samples were stored at 50°C for 30 minutes in a water bath. Results showed that Copovidone successfully preserved integrity and biological activity of lysozyme before and after storage in both spray-dried and freezedried forms with more advantage for using higher concentration of the same excipient.
Introduction

1
Among all of the biological macromolecules, proteins embrace an exceptional heterogeneous 2 class. Protein-based therapeutics has found to be an effective treatment for wide spectrum of 3 diseases (1), e.g. diabetes, infections, inflammation, wound healing, decubital ulcers, sunburn 4 etc. However, protein therapeutics suffers from the inadequate stability, especially in aqueous 5 form (2), as a result of protein aggregation by the effect of protein unfolding or surface 6 interaction between the hydrophobic residues within the proteins (3). This is consider the 7 major drawback of such a drug. Proteins are marginally stable in solid form but prone for 8 physical degradation.
10
Several methods were applied in order to overcome the challenges associated with protein 11 stability. The most frequently used method to produce solid state protein formulations with a 12 considerable stability is spray drying (see for example, (2,4,5) and freeze drying (see for 13 example, (6) (7) (8) . Another method used to stabilise proteins is by adding wide variety of 14 excipients to stabilise proteins (see for example, (2,9,10).
16
Spray drying is a one-step liquid atomization technique wildly used to produce solid 17 pharmaceutical dosage forms. This process can utilise micro-and nano-size scaled particles 18 that are suitable for pulmonary administration (2). Protein spray-dried particles prepared 19 using this technique were developed either alone or with the addition of some stabilising 20 excipients. So far, different excipients were used in order to obtain a stable protein 21 formulation using spray drying method include sugars (e.g. trehalose (10)), surfactants (e.g.
22
pluronic F-127®(2), polyols (e.g. sorbitol (11)), polymers (e.g. dextran and polyethylene 23 glycol (12)), antioxidants (e.g. ethylenediaminetetraacetic acid (13)), amino acids (e.g. 24 ascorbic (13)), chelating agents (e.g. ammonium sulphate (14)).
26
Freeze drying method is a sublimation based technique commonly used for heat sensitive 27 materials to increase their stability and shelf life as pharmaceutical products. This technique 28 involves two steps: freezing and drying. A drastic reduction in the hydration of the proteins is The mechanism by which all of the additives works is not very clear. However, there are The purpose of this study is to investigate the effects of three copolymers named 51 (Copovidone, Eudragit® RL PO and Kollicoat® MAE 30 DP) on spray-dried and freeze-52 dried lysozyme (as a model protein) thermal stability, integrity and biological activity before 53 and after storage. Both drying processes were chosen for subjecting the protein to two 54 different drying conditions using high temperature (during spray drying) and low temperature 55 (during freeze drying). Copovidone is a copolymer of 1-vinyl-2-pyrrolidone and vinyl acetate 56 (60:40 ratio). It is used in cosmetic and pharmaceutical preparations as a tablet binder, form a 57 protective layer in film coating on tablets, film-forming agent in spray and effective in 58 controlled drug release formulations. This excipient has a stabilising effect on lysozyme in 59 aqueous media (23), however, its effect on lysozyme in dried forms is still unknown. Solutions were let to freeze at -85 ˚C for 4 hr followed by lyophilisation for 48 hours at a 106 pressure of 10mBar, condenser temperature of -100 ± 2 ˚C and shelf temperature of 21 ˚C.
107
Shelf temperature was kept at 21 ˚C during the whole freeze drying process; meaning that 108 protein samples were dried using primary drying step in which the sublimation of ice takes 
Microscopic examination of spray-dried and freeze-dried lysozyme formulations
122
The morphologies of the spray-dried and freeze-dried protein particles were inspected using 
126
The samples were coated with a mixture of gold/palladium using a Quorum Technology has an effect on particle shape and density when spray-dried with the protein.
213
The morphology of spray-dried particles has a significant role in the aerodynamic properties PO) managed to stabilise lysozyme conformational structure throughout the drying processes.
291
The secondary structure of proteins can be detected in the IR region of Amide I vibration spray-dried and freeze-dried lysozyme formulations.
298
Insert Fig 3
299
Unprocessed lysozyme (as received) had Amide I and II peaks at 1645 and 1538 cm -1 ,
300
respectively. The biggest shift (+14cm -1 ) of Amide I peak was found for freeze-dried 301 lysozyme: Eudragit® RL PO (1:0.5 weight ratio) sample (Fig 3j) as compared to the control 302 lysozyme spectrum (Fig 3a) . This was considered as the biggest change. Therefore, +/-1cm -1
303
was considered as minor shift and anything more than that was considered as major shift in 304 peak position (28). Freeze drying of lysozyme without any excipient preserved the secondary 305 structure and conformation integrity of lysozyme to a great extent in both Amide I and II 306 bands (Fig 3c) . Whereas, spray drying of lysozyme without excipients (Fig 3b) disturbed the 307 secondary structure of lysozyme as there were major changes in the shapes and shifts in both (Fig 3g,h, respectively) , preserved the secondary structure and conformation integrity of 314 lysozyme. However, spray drying of lysozyme with Copovidone (0.2 and 0.5% w/v) revealed 315 major shifts of Amide I band by +6cm -1 (Fig 3d,e, respectively Copovidone (81%)). Accordingly, the effect of the used excipients was the same for both 366 proteins (lysozyme and trypsin, which is more thermolabile compared to lysozyme).
367
Lysozyme formulations were subjected to stability study. It was found that unprocessed 368 lysozyme had lost ~19.8% of its bioactivity when stored at high relative humidity and ~15%
369
at high temperature, as compared with the unprocessed lysozyme before storage (Fig 4) .
370
More than 90% of lysozyme biological activity was preserved for freeze-dried and spray-371 dried lysozyme with Copovidone (using both weight ratios 1:0.2 and 1:0.5) compared to that 372 of fresh protein formulations. Interestingly, the biological activity of protein was increased 373 for freeze-dried lysozyme with Eudragit® RL PO.
374
All samples showed a significant reduction of proteins activity upon storage at 50̊C for 30min 
